Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria

Background/Aims Ustekinumab is effective in active Crohn’s disease. In a retrospective study, we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin inhibitor vedolizumab. As approval study populations do not alwa...

Full description

Bibliographic Details

Published in:	Intestinal Research
Main Authors:	Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
Format:	Article
Language:	English
Published:	Korean Association for the Study of Intestinal Diseases 2019-07-01
Subjects:	Crohn disease Ustekinumab Biological therapy
Online Access:	http://www.irjournal.org/upload/pdf/ir-2019-00012.pdf